Abstract:Following our previous work on human immunodeficiency virus-1 (HIV-1) non-nucleoside reverse transcriptase inhibitors (NNRTIs), a series of novel biphenyl-pyridone derivatives were synthesized and evaluated for their anti-HIV-1 activity to expand their structure–activity relationship. Some of them exhibited low nanomolar activity toward wild-type HIV-1 and clinically relevant single/double mutant strains. The most active compound B1 was 231-fold more potent (EC50 = 17 nmol/L) than the lead compound 2 (EC50 = 3.93 μmol/L) against wild-type (WT) HIV-1. This compound was approximately 3.5-fold less cytotoxic (CC50 = 100.58 μmol/L) than compound 2 (CC50 = 28.24 μmol/L), presenting a higher selectivity index (SI) value of 5923. Compared with 2, the antiviral potency of B1 was significantly increased against five single mutant strains (L100I, K103N, E138K, Y181C and Y188L) and two double mutant strains (F227L+V106A and K103N+Y181C). Especially, K103N, Y181C and K103N+Y181C were more sensitive to B1 than both 2 and doravirine. Besides, the enzymatic inhibitory activity of B1 against wild-type HIV-1 reverse transcriptase was approximately 32-fold higher (IC50 = 100 nmol/L) than 2 (IC50 = 3.21 μmol/L). Molecular docking studies and dynamic simulations were conducted to explain their potent activity. Taken together, this research represents an important step toward the discovery of novel biphenyl-pyridone drug candidates for HIV therapy.

Preliminary SAR and Biological Evaluation of Potent HIV-1 Protease Inhibitors with Pyrimidine Bases As Novel P2 Ligands to Enhance Activity Against DRV-resistant HIV-1 Variants

Design, Synthesis, and Biological Evaluation of Novel HIV-1 Protease Inhibitors Containing Pyrrolidine-Derived P2 Ligands to Combat Drug-Resistant Variant

Design and Evaluation of Novel HIV-1 Protease Inhibitors Containing Phenols or Polyphenols as P2 Ligands with High Activity against DRV-Resistant HIV-1 Variants

Design and Evaluation of Novel Piperidine HIV-1 Protease Inhibitors with Potency Against DRV-resistant Variants

Synthesis and evaluation of potent human immunodeficiency virus 1 protease inhibitors with epimeric isopropanol as novel P1 ligands

Design and Biological Evaluation of Novel HIV-1 Protease Inhibitors with Isopropanol As P1′ Ligand to Enhance Binding with S1′ Subsite

A kind of HIV-1 protease inhibitors containing phenols with antiviral activity against DRV-resistant variants

Design, synthesis and biological evaluation of protease inhibitors containing morpholine cores with remarkable potency against both HIV-1 subtypes B and C

Novel HIV-1 Protease Inhibitors with Morpholine As the P2 Ligand to Enhance Activity Against DRV-Resistant Variants

Evaluation of Novel HIV-1 Protease Inhibitors with DRV-resistance by Utilizing 3D-QSAR Molecular Docking and Molecular Dynamics Simulation

Design and Synthesis of Potent HIV-1 Protease Inhibitors with (S)-Tetrahydrofuran-tertiary Amine-Acetamide As P2−ligand: Structure−activity Studies and Biological Evaluation

Design and Biological Evaluation of Cinnamic and Phenylpropionic Amide Derivatives As Novel Dual Inhibitors of HIV-1 Protease and Reverse Transcriptase

Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives As Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency Against Resistance-Associated Variants

Design, Synthesis, and Biological Evaluation of Novel 5-Alkyl-6-adamantylmethylpyrimidin-4(3h)-ones As Hiv-1 Non-Nucleoside Reverse-Transcriptase Inhibitors

Synthesis and biological evaluation of new HIV-1 protease inhibitors with purine bases as P2-ligands.

Structure-directed expansion of biphenyl-pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with significantly improved potency and safety

Design, Synthesis and Anti-Hiv Evaluation of Novel Diarylpyridine Derivatives As Potent HIV-1 NNRTIs.

Hybrid Diarylbenzopyrimidine Non-Nucleoside Reverse Transcriptase Inhibitors As Promising New Leads for Improved Anti-Hiv-1 Chemotherapy

Design, Synthesis and Biological Evaluation of 3-Benzyloxy-linked Pyrimidinylphenylamine Derivatives As Potent HIV-1 NNRTIs.

Design, Synthesis and Biological Evaluation of HIV-1 Protease Inhibitors with Morpholine Derivatives As P2 Ligands in Combination with Cyclopropyl As P1' Ligand.

Synthesis And Biological Evaluation Of Novel 5-Alkyl-2-Arylthio-6-((3,4-Dihydroquinolin-1(2h)-Yl)Methyl)Pyrimidin-4(3 H)-Ones As Potent Non-Nucleoside Hiv-1 Reverse Transcriptase Inhibitors